| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8667048622d41a8c708023c6e5f65d74
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2b9e5ef4b874481e60a4d94f8c98233d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bb273ab355edf3f6ffa55a32514c6bf5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c0cae666875d75829663b24ab400c4d8 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-404
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-635
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4439
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-496 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-015
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N1-00 |
| filingDate |
2015-05-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_621631d4d27e18e416ee961ba1d9305b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_80eba58b79f1a91ebb30848374a17921
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_285e0e0f659c9a4a69d8afda482f2de7 |
| publicationDate |
2015-11-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2015171957-A1 |
| titleOfInvention |
Plasmodium liver-stage inhibitors and related methods |
| abstract |
The present disclosure provides for methods of addressing the devastating effects of malaria infection by mosquito-borne Plasmodium parasites. The methods include the administration of an effective amount of at least one pro-apoptotic agent and the administration of an effective amount of at least one p53 activator. The at least one pro-apoptotic agent can be administered concurrently with, prior to, or subsequent to the at least one p53 activator. The at least one pro-apoptotic agent and/or at least one p53 activator can be administered concurrently with, prior to, or subsequent to exposure of a hepatocyte ( in vivo or i n vitro ) by a Plasmodium parasite. In some embodiments, the administration of the at least one pro-apoptotic agent combined with the administration of the at least one p53 activator results in clearance of hypnozoite stage of P. vivax or P. ovale , and thus prevents relapse of symptoms and disease from the infection of these parasites. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-4257133-A1 |
| priorityDate |
2014-05-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |